Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics

References

• Hodson R. Inflammatory bowel disease. Nature. 2016;540(7634):S97. doi:10.1038/540S97a
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603–617.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Berends SE, Strik AS, Jansen JM, et al. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scand J Gastroenterol. 2019;54:700–706.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Nguyen DD, Beattie DT, et al. Development of gut-selective Pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohns Colitis. 2020;14:1202–1213.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70:1396–1405.
   PubMed Web of Science ®Google Scholar
• Chang X, Yang MF, Fan W, et al. Bioinformatic analysis suggests that three hub genes may be a vital prognostic biomarker in pancreatic ductal adenocarcinoma. J Comput Biol. 2020;27(11):1595–1609.
   PubMed Web of Science ®Google Scholar
• Shastry RP, Rekha PD. Bacterial cross talk with gut microbiome and its implications: a short review. Folia Microbiol (Praha). 2021;66(1):15–24. doi:10.1007/s12223-020-00821-5
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–237. doi:10.1038/s41575-019-0258-z
   PubMed Web of Science ®Google Scholar
• Kumar S, Kumar A. Microbial pathogenesis in inflammatory bowel diseases. Microb Pathog. 2021;163:105383. doi:10.1016/j.micpath.2021.105383
   PubMed Web of Science ®Google Scholar
• Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021;19(3):265–274. doi:10.5217/ir.2020.00045
   PubMed Web of Science ®Google Scholar
• An D, Oh SF, Olszak T, et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014;156:123–133.
   PubMed Web of Science ®Google Scholar
• Troy EB, Kasper DL. Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Front Biosci. 2010;15:25–34.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–230.
   PubMed Web of Science ®Google Scholar
• Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191.
   PubMed Web of Science ®Google Scholar
• Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol. 2014;20:1192–1210.
   PubMed Web of Science ®Google Scholar
• DeGruttola AK, Low D, Mizoguchi A, et al. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22:1137–1150.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780–13785.
   PubMed Web of Science ®Google Scholar
• Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
   PubMed Web of Science ®Google Scholar
• Parent K, Mitchell P. Cell wall-defective variants of pseudomonas-like (group Va) bacteria in Crohn’s disease. Gastroenterology. 1978;75:368–372.
   PubMed Web of Science ®Google Scholar
• Chervy M, Barnich N, Denizot J. Adherent-invasive E. coli: update on the lifestyle of a troublemaker in Crohn’s disease. Int J Mol Sci. 2020;21:3734.
   PubMed Web of Science ®Google Scholar
• Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655–662.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–16736.
   PubMed Web of Science ®Google Scholar
• Rossi O, van Berkel LA, Chain F, et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016;6:18507.
   PubMed Web of Science ®Google Scholar
• Britton GJ, Contijoch EJ, Mogno I, et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORgammat(+) regulatory T cells and exacerbate colitis in mice. Immunity. 2019;50:212–224 e4.
   PubMed Web of Science ®Google Scholar
• Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321:156–164.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118 e4.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhao W, Lan P, et al. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell. 2021;12:331–345.
   PubMed Web of Science ®Google Scholar
• Dalile B, Van Oudenhove L, Vervliet B, et al. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16:461–478.
   PubMed Web of Science ®Google Scholar
• Brown EM, Kenny DJ, Xavier RJ. Gut microbiota regulation of T cells during inflammation and autoimmunity. Annu Rev Immunol. 2019;37:599–624.
   PubMed Web of Science ®Google Scholar
• Li F, Xiong F, Xu ZL, et al. Polyglycolic acid sheets decrease post-endoscopic submucosal dissection bleeding in early gastric cancer: a systematic review and meta-analysis. J Dig Dis. 2020;21:437–444.
   PubMed Web of Science ®Google Scholar
• Banfi D, Moro E, Bosi A, et al. Impact of microbial metabolites on microbiota-gut-brain axis in inflammatory bowel disease. Int J Mol Sci. 2021;22:1623.
   PubMed Web of Science ®Google Scholar
• Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14:9–21.
   PubMed Web of Science ®Google Scholar
• Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol. 2017;35:119–147.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Gustafsson JK, Holmen-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63:281–291.
   PubMed Web of Science ®Google Scholar
• Martini E, Krug SM, Siegmund B, et al. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4:33–46.
   PubMed Web of Science ®Google Scholar
• Dorofeyev AE, Vasilenko IV, Rassokhina OA, et al. Mucosal barrier in ulcerative colitis and Crohn’s disease. Gastroenterol Res Pract. 2013;2013:431231.
   PubMed Web of Science ®Google Scholar
• Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117–129.
   PubMed Web of Science ®Google Scholar
• Parikh K, Antanaviciute A, Fawkner-Corbett D, et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature. 2019;567:49–55.
   PubMed Web of Science ®Google Scholar
• Pott J, Hornef M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep. 2012;13:684–698.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4:e7984.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Nakamura K, Yoshii A, et al. Paneth cell alpha-defensin misfolding correlates with dysbiosis and ileitis in Crohn’s disease model mice. Life Sci Alliance. 2020;3. doi:10.26508/lsa.201900592
   Web of Science ®Google Scholar
• Ramanan D, Cadwell K. Intrinsic defense mechanisms of the intestinal epithelium. Cell Host Microbe. 2016;19:434–441.
   PubMed Web of Science ®Google Scholar
• Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119–144.
   PubMed Web of Science ®Google Scholar
• Al-Sadi R, Nighot P, Nighot M, et al. Lactobacillus acidophilus induces a strain-specific and toll-like receptor 2-dependent enhancement of intestinal epithelial tight junction barrier and protection against intestinal inflammation. Am J Pathol. 2021;191:872–884.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 2007;56:61–72.
   PubMed Web of Science ®Google Scholar
• Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol. 2013;14:660–667.
   PubMed Web of Science ®Google Scholar
• Su L, Nalle SC, Shen L, et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology. 2013;145:407–415.
   PubMed Web of Science ®Google Scholar
• Ma TY, Boivin MA, Ye D, et al. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol. 2005;288:G422–30.
   PubMed Web of Science ®Google Scholar
• Knutson CG, Mangerich A, Zeng Y, et al. Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2013;110:E2332–41.
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–241.
   PubMed Web of Science ®Google Scholar
• Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20:6–21.
   PubMed Web of Science ®Google Scholar
• Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3–10.
   PubMed Web of Science ®Google Scholar
• Holleran G, Lopetuso L, Petito V, et al. The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease. Int J Mol Sci. 2017;18:2020.
   PubMed Web of Science ®Google Scholar
• Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev. 2005;206:149–159.
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298–306.
   PubMed Web of Science ®Google Scholar
• Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50–65.
   PubMed Web of Science ®Google Scholar
• Malmstrom V, Shipton D, Singh B, et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol. 2001;166:6972–6981.
   PubMed Web of Science ®Google Scholar
• Lai LJ, Shen J, Ran ZH. Natural killer T cells and ulcerative colitis. Cell Immunol. 2019;335:1–5.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016;8:2490–2497.
   PubMed Web of Science ®Google Scholar
• Nagasawa M, Spits H, Ros XR. Innate Lymphoid Cells (ILCs): cytokine hubs regulating immunity and tissue homeostasis. Cold Spring Harb Perspect Biol. 2018;10:a030304.
   PubMed Web of Science ®Google Scholar
• Mjosberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138:1265–1276.
   PubMed Web of Science ®Google Scholar
• Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054–1066.
   PubMed Web of Science ®Google Scholar
• Kramer B, Goeser F, Lutz P, et al. Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy. PLoS Pathog. 2017;13:e1006373.
   PubMed Web of Science ®Google Scholar
• Forkel M, van Tol S, Hoog C, et al. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67–78.
   PubMed Web of Science ®Google Scholar
• Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221–229.
   PubMed Web of Science ®Google Scholar
• Creyns B, Jacobs I, Verstockt B, et al. Biological therapy in inflammatory bowel disease patients partly restores intestinal innate lymphoid cell subtype equilibrium. Front Immunol. 2020;11:1847.
   PubMed Web of Science ®Google Scholar
• Schulz-Kuhnt A, Wirtz S, Neurath MF, et al. Regulation of human innate lymphoid cells in the context of mucosal inflammation. Front Immunol. 2020;11:1062.
   PubMed Web of Science ®Google Scholar
• Hu Z, Zou Q, Su B. Regulation of T cell immunity by cellular metabolism. Front Med. 2018;12:463–472.
   PubMed Web of Science ®Google Scholar
• Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther. 2015;97:22–28.
   PubMed Web of Science ®Google Scholar
• Jovani M, Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets. 2013;14:1433–1443.
   PubMed Web of Science ®Google Scholar
• Muhl L, Becker E, Muller TM, et al. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol. 2021;21:33.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Vermeire S, Tyrrell H, et al. Etrolizumab for the treatment of ulcerative colitis and Crohn’s disease: an overview of the phase 3 clinical program. Adv Ther. 2020;37:3417–3431.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Sato T, Kamada N, et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn’s disease. Gastroenterology. 2009;137:1736–1745.
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–533.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74:5–17.
   PubMed Web of Science ®Google Scholar
• Caza T, Landas S. Functional and Phenotypic Plasticity of CD4(+) T Cell Subsets. Biomed Res Int. 2015;2015:521957.
   PubMed Web of Science ®Google Scholar
• Woznicki JA, Saini N, Flood P, et al. TNF-alpha synergises with IFN-gamma to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. Cell Death Dis. 2021;12:864.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–1132.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–974.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585–600.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu Q, Liu Y, et al. Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies. J Immunol Res. 2021;2021:8816041.
   PubMed Web of Science ®Google Scholar
• Diaz Pena R, Valdes E, Cofre C, et al. Th17 response and autophagy–main pathways implicated in the development of inflammatory bowel disease by genome-wide association studies. Rev Esp Enferm Dig. 2015;107:559–565.
   PubMedGoogle Scholar
• Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57:1682–1689.
   PubMed Web of Science ®Google Scholar
• Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:382–388.
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063–1075.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:368–371.
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756–1767.
   PubMed Web of Science ®Google Scholar
• Galvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461.
   PubMedGoogle Scholar
• Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–1878.
   PubMed Web of Science ®Google Scholar
• Mayne CG, Williams CB. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1772–1788.
   PubMed Web of Science ®Google Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302–316.
   PubMed Web of Science ®Google Scholar
• Ohnmacht C, Park JH, Cording S, et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORgammat(+) T cells. Science. 2015;349:989–993. doi:10.1126/science.aac4263
   PubMed Web of Science ®Google Scholar
• Acharya S, Timilshina M, Jiang L, et al. Amelioration of experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation. Sci Rep. 2018;8(1):7799. doi:10.1038/s41598-018-26088-y
   PubMed Web of Science ®Google Scholar
• Yu R, Zuo F, Ma H, et al. Exopolysaccharide-producing bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 Axis of DSS-colitis mice. Nutrients. 2019;11(4):782. doi:10.3390/nu11040782
   PubMed Web of Science ®Google Scholar
• Holmen N, Lundgren A, Lundin S, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12(6):447–456. doi:10.1097/00054725-200606000-00003
   PubMed Web of Science ®Google Scholar
• Lee YK, Mukasa R, Hatton RD, et al. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 2009;21(3):274–280. doi:10.1016/j.coi.2009.05.021
   PubMed Web of Science ®Google Scholar
• Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014;15(12):1104–1115. doi:10.1038/ni.3031
   PubMed Web of Science ®Google Scholar
• Gebhardt T, Wakim LM, Eidsmo L, et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524–530. doi:10.1038/ni.1718
   PubMed Web of Science ®Google Scholar
• Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21(7):688–697. doi:10.1038/nm.3883
   PubMed Web of Science ®Google Scholar
• Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652–2664.
   PubMed Web of Science ®Google Scholar
• Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol. 2020;55:90–98. doi:10.1016/j.coph.2020.10.002
   PubMed Web of Science ®Google Scholar
• Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28(6):740–750. doi:10.1016/j.immuni.2008.05.001
   PubMed Web of Science ®Google Scholar
• Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206(1):83–99. doi:10.1111/j.0105-2896.2005.00278.x
   PubMed Web of Science ®Google Scholar
• Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol. 2009;9(1):15–27. doi:10.1038/nri2454
   PubMed Web of Science ®Google Scholar
• Uo M, Hisamatsu T, Miyoshi J, et al. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcgammaR-mediated CD14 macrophage activation. Gut. 2013;62:1734–1744. doi:10.1136/gutjnl-2012-303063
   PubMed Web of Science ®Google Scholar
• Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to Anti-TNF therapy. Cell. 2019;178(6):1493–1508 e20. doi:10.1016/j.cell.2019.08.008
   PubMed Web of Science ®Google Scholar
• Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut. 2011;60(11):1520–1526. doi:10.1136/gut.2010.225482
   PubMed Web of Science ®Google Scholar
• Boland BS, He Z, Tsai MS, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020;5:eabb4432.
   PubMed Web of Science ®Google Scholar
• Zhou L, Sonnenberg GF. Essential immunologic orchestrators of intestinal homeostasis. Sci Immunol. 2018;3:eaao1605.
   PubMed Web of Science ®Google Scholar
• Fung TC, Bessman NJ, Hepworth MR, et al. Lymphoid-tissue-resident commensal bacteria promote members of the IL-10 cytokine family to establish mutualism. Immunity. 2016;44(3):634–646. doi:10.1016/j.immuni.2016.02.019
   PubMed Web of Science ®Google Scholar
• Pham TA, Clare S, Goulding D, et al. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe. 2014;16(4):504–516. doi:10.1016/j.chom.2014.08.017
   PubMed Web of Science ®Google Scholar
• Fukui H, Sekikawa A, Tanaka H, et al. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowel Dis. 2011;17(5):1177–1188. doi:10.1002/ibd.21473
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Calafiore M, Mertelsmann AM, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015;528(7583):560–564. doi:10.1038/nature16460
   PubMed Web of Science ®Google Scholar
• Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn’s disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis. 2000;15(4):206–210. doi:10.1007/s003840000226
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 2008;1(3):175–182. doi:10.1038/mi.2008.7
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6(5):583–588. doi:10.1038/75068
   PubMed Web of Science ®Google Scholar
• Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases - Update 2020. Pharmacol Res. 2020;158:104835. doi:10.1016/j.phrs.2020.104835
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–146. doi:10.1038/nri1001
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725. doi:10.1016/S1074-7613(00)00070-4
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729. doi:10.1038/nm.3895
   PubMed Web of Science ®Google Scholar
• Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564–568. doi:10.1038/nature13577
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181. doi:10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• Wei H, Li B, Sun A, et al. Interleukin-10 family cytokines immunobiology and structure. Adv Exp Med Biol. 2019;1172:79–96.
   PubMed Web of Science ®Google Scholar
• Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–2045. doi:10.1056/NEJMoa0907206
   PubMed Web of Science ®Google Scholar
• Mas-Orea X, Sebert M, Benamar M, et al. Peripheral opioid receptor blockade enhances epithelial damage in piroxicam-accelerated colitis in IL-10-deficient mice. Int J Mol Sci. 2021;22:7387.
   PubMed Web of Science ®Google Scholar
• Saha P, Golonka RM, Abokor AA, et al. IL-10 receptor neutralization-induced colitis in mice: a comprehensive guide. Curr Protoc. 2021;1:e227.
   PubMedGoogle Scholar
• Xu M, Pokrovskii M, Ding Y, et al. c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature. 2018;554:373–377.
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553–562.
   PubMed Web of Science ®Google Scholar
• Rodrigues VF, Bahia MPS, Candido NR, et al. Acute infection with Strongyloides venezuelensis increases intestine production IL-10, reduces Th1/Th2/Th17 induction in colon and attenuates dextran sulfate sodium-induced colitis in BALB/c mice. Cytokine. 2018;111:72–83.
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15:458–469.
   PubMed Web of Science ®Google Scholar
• Li B, Alli R, Vogel P, et al. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol. 2014;7:869–878.
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease–enhanced production during active disease. Gut. 1990;31:686–689.
   PubMed Web of Science ®Google Scholar
• Liu L, Dong Y, Ye M, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis. 2017;11:737–750.
   PubMed Web of Science ®Google Scholar
• Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A. 2001;98:13249–13254.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Novick D, Kim S, et al. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.
   PubMed Web of Science ®Google Scholar
• Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol. 2013;4:181.
   PubMed Web of Science ®Google Scholar
• Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20:2529.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Bouhnik Y, Cummings F, et al. Enhancing treatment success in inflammatory bowel disease: optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis. 2020;52:1259–1265.
   PubMedGoogle Scholar
• Ngo B, Farrell CP, Barr M, et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr Mol Pharmacol. 2010;3:145–152.
   PubMedGoogle Scholar
• Shih DQ, Michelsen KS, Barrett RJ, et al. Insights into TL1A and IBD pathogenesis. Adv Exp Med Biol. 2011;691:279–288.
   PubMed Web of Science ®Google Scholar
• Siakavellas SI, Bamias G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation. Inflamm Bowel Dis. 2015;21:2441–2452.
   PubMed Web of Science ®Google Scholar
• Castellanos JG, Woo V, Viladomiu M, et al. Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity. 2018;49:1077–1089 e5.
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med. 2000;343:1020–1034.
   PubMed Web of Science ®Google Scholar
• Habtezion A, Nguyen LP, Hadeiba H, et al. Leukocyte trafficking to the small intestine and colon. Gastroenterology. 2016;150:340–354.
   PubMed Web of Science ®Google Scholar
• Kim SV, Xiang WV, Kwak C, et al. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science. 2013;340:1456–1459.
   PubMed Web of Science ®Google Scholar
• Trivett MT, Burke JD, Deleage C, et al. Preferential small intestine homing and persistence of CD8 T cells in rhesus macaques achieved by molecularly engineered expression of CCR9 and reduced ex vivo manipulation. J Virol. 2019;93:e00896–19.
   PubMed Web of Science ®Google Scholar
• Sun H, Liu J, Zheng Y, et al. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell. 2014;30:61–70.
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol. 2003;3:867–878.
   PubMed Web of Science ®Google Scholar
• Denucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol. 2009;29:87–109.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346–349.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355–360.
   PubMed Web of Science ®Google Scholar
• Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8:1147–1165.
   PubMed Web of Science ®Google Scholar
• Latella G, Di Gregorio J, Flati V, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2015;50:53–65.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Rogler G, Bamias G, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. 2017;11:1491–1503.
   PubMed Web of Science ®Google Scholar
• Yun SM, Kim SH, Kim EH. The molecular mechanism of transforming growth factor-beta signaling for intestinal fibrosis: a mini-review. Front Pharmacol. 2019;10:162.
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang G, Elias M, et al. The role of cytokine and immune responses in intestinal fibrosis. J Dig Dis. 2020;21:308–314.
   PubMed Web of Science ®Google Scholar
• Latella G. Redox imbalance in intestinal fibrosis: beware of the TGFbeta-1, ROS, and Nrf2 connection. Dig Dis Sci. 2018;63:312–320.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009;58:777–789.
   PubMed Web of Science ®Google Scholar
• Rieder F, Kessler S, Sans M, et al. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303:G786–801.
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–584.
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Miyazono K. Regulation of TGF-beta family signaling by inhibitory smads. Cold Spring Harb Perspect Biol. 2017;9:a022095.
   PubMed Web of Science ®Google Scholar
• Ramani K, Biswas PS. Interleukin-17: friend or foe in organ fibrosis. Cytokine. 2019;120:282–288.
   PubMed Web of Science ®Google Scholar
• Biancheri P, Pender SL, Ammoscato F, et al. The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair. 2013;6:13.
   PubMedGoogle Scholar
• Honzawa Y, Nakase H, Shiokawa M, et al. Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn’s disease. Gut. 2014;63:1902–1912.
   PubMed Web of Science ®Google Scholar
• Li J, Liu L, Zhao Q, et al. Role of interleukin-17 in pathogenesis of intestinal fibrosis in mice. Dig Dis Sci. 2020;65:1971–1979.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700.
   PubMed Web of Science ®Google Scholar
• Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14:4280–4288.
   PubMed Web of Science ®Google Scholar
• Drygiannakis I, Valatas V, Sfakianaki O, et al. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. J Crohns Colitis. 2013;7:286–300.
   PubMed Web of Science ®Google Scholar
• Meylan F, Song YJ, Fuss I, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4:172–185.
   PubMed Web of Science ®Google Scholar
• Barrett R, Zhang X, Koon HW, et al. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol. 2012;180:636–649.
   PubMed Web of Science ®Google Scholar
• Adler J, Rahal K, Swanson SD, et al. Anti-tumor necrosis factor alpha prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn’s disease. Inflamm Bowel Dis. 2013;19:683–690.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–1038.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389:1710–1718.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583–594.
   PubMed Web of Science ®Google Scholar
• GK H. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111:677–90;quiz 691.
   Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99–106.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology. 2008;135:2003–13, 2013 e1–7.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188:1929–1939.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Panes J, Khurana S, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015;64:894–900.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–1040.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res. 1995;21:791–808.
   PubMed Web of Science ®Google Scholar
• Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int. 1999;56:2116–2127.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222–228.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Lin S, Moore M, et al. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10:2040622319838443.
   Web of Science ®Google Scholar
• Feagan BG, Panes J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3:671–680.
   PubMed Web of Science ®Google Scholar
• Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a Phase 2a study. Gastroenterology. 2017;153:77–86 e6.
   PubMed Web of Science ®Google Scholar
• Ma C, Jairath V, Khanna R, et al. Investigational drugs in Phase I and Phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2018;27:649–660.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2021;162:495–508.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV Jr., et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158:2123–2138 e8.
   PubMed Web of Science ®Google Scholar
• Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50:5–23.
   PubMed Web of Science ®Google Scholar
• Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn’s disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18:2203–2208.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lee SD, Tarabar D, et al. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. Gut. 2018;67:1824–1835.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Lakatos PL, Ritter T, et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2021;7:28–37.
   PubMed Web of Science ®Google Scholar
• Hibi T, Motoya S, Ashida T, et al. Efficacy and safety of abrilumab, an alpha4beta7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res. 2019;17:375–386.
   PubMed Web of Science ®Google Scholar
• Cario E. Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond. Curr Opin Gastroenterol. 2010;26:583–590.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Fornai M, Colucci R, et al. A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. Front Pharmacol. 2018;9:1405.
   PubMed Web of Science ®Google Scholar
• Liu G, Mateer SW, Hsu A, et al. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome. Mucosal Immunol. 2019;12:862–873.
   PubMed Web of Science ®Google Scholar
• Du X, Chen W, Wang Y, et al. Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-kappaB activation. Int Immunopharmacol. 2017;45:16–25.
   PubMed Web of Science ®Google Scholar
• Fan M, Xiang G, Chen J, et al. Libertellenone M, a diterpene derived from an endophytic fungus Phomopsis sp. S12, protects against DSS-induced colitis via inhibiting both nuclear translocation of NF-kappaB and NLRP3 inflammasome activation. Int Immunopharmacol. 2020;80:106144.
   PubMed Web of Science ®Google Scholar